Compare Fortinet Inc (FTNT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Organon & Co. Common Stock — how do they compare? Fortinet Inc trades at $181.75 (market cap $139.96B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Fortinet Inc is far larger — about 38.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Organon & Co. Common Stock for 0 Days on average.
| FTNT | OGN | |
|---|---|---|
Market Cap | $139.96B | $3.62B |
Volume | 2,774,680 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $194.75 | $13.81 |
52-Week Low | $75.23 | $5.70 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $136.39B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $184.05, down 4.61% today, but maintains a bullish technical trend with strong fundamental performance. The company reported revenue of $6.80B in 2025 with a net income margin of 28.17%, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its leadership in AI-driven cybersecurity and robust platform demand, with the stock nearing its 52-week high.
The outlook remains positive given strong earnings beats and raised 2026 guidance, though high valuation ratios (P/E 67.41) and competitive pressures pose risks. Analyst consensus is mixed with 42% buy ratings, but a $160.24 price target suggests caution relative to the current price. Institutional interest is growing, supporting momentum.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
